Cargando…

A risk model of gene signatures for predicting platinum response and survival in ovarian cancer

BACKGROUND: Ovarian cancer (OC) is the deadliest tumor in the female reproductive tract. And increased resistance to platinum-based chemotherapy represents the major obstacle in the treatment of OC currently. Robust and accurate gene expression models are crucial tools in distinguishing platinum the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Siyu, Wu, Yong, Wang, Simin, Wu, Jiangchun, Wu, Xiaohua, Zheng, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973612/ https://www.ncbi.nlm.nih.gov/pubmed/35361267 http://dx.doi.org/10.1186/s13048-022-00969-3

Ejemplares similares

RNA-binding proteins in ovarian cancer: a novel avenue of their roles in diagnosis and treatment
por: Wu, Jiangchun, et al.
Publicado: (2022)

SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization
por: Wu, Jiangchun, et al.
Publicado: (2022)

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
por: Chen, Wei, et al.
Publicado: (2020)

Developing a nomogram for preoperative prediction of cervical cancer lymph node metastasis by multiplex immunofluorescence
por: Wu, Jiangchun, et al.
Publicado: (2023)

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
por: Wu, Yong, et al.
Publicado: (2023)

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma
por: Liu, Gang, et al.
Publicado: (2018)

Bioinformatic profiling identifies a platinum‐resistant–related risk signature for ovarian cancer
por: Wu, Ce, et al.
Publicado: (2019)

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
por: Murakami, Ryusuke, et al.
Publicado: (2021)

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
por: Mairinger, Fabian, et al.
Publicado: (2019)

Identification of a glycolysis‐related gene signature for survival prediction of ovarian cancer patients
por: Zhang, Dai, et al.
Publicado: (2021)

An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
por: Qi, Lishuang, et al.
Publicado: (2016)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer
por: Guo, Kaidi, et al.
Publicado: (2021)

A Platinum Resistance-Related lncRNA Signature for Risk Classification and Prognosis Prediction in Patients with Serous Ovarian Cancer
por: Zhu, Yan, et al.
Publicado: (2022)

Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer
por: Li, He, et al.
Publicado: (2022)

Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy
por: Sun, Jie, et al.
Publicado: (2019)

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
por: Wen, Hao, et al.
Publicado: (2022)

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer
por: Du, Pei, et al.
Publicado: (2016)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
por: Liu, Rong, et al.
Publicado: (2017)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis
por: Gunderson, Camille C, et al.
Publicado: (2022)

Amino acid metabolism‐related gene expression‐based risk signature can better predict overall survival for glioma
por: Liu, Yu‐Qing, et al.
Publicado: (2018)

An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma
por: Wu, Yuxin, et al.
Publicado: (2023)

A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer
por: Ding, Qi, et al.
Publicado: (2020)

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
por: Rae, Sophie, et al.
Publicado: (2022)

Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts
por: Merrill, Daniel, et al.
Publicado: (2016)

Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma
por: Zheng, Susu, et al.
Publicado: (2021)

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
por: Sheng, W.J., et al.
Publicado: (2013)

Network-based Survival Analysis Reveals Subnetwork Signatures for Predicting Outcomes of Ovarian Cancer Treatment
por: Zhang, Wei, et al.
Publicado: (2013)

SERPINB3 in the Chicken Model of Ovarian Cancer: A Prognostic Factor for Platinum Resistance and Survival in Patients with Epithelial Ovarian Cancer
por: Lim, Whasun, et al.
Publicado: (2012)

An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma
por: Zhang, Liuyan, et al.
Publicado: (2019)

ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer
por: Hua, Tian, et al.
Publicado: (2021)

A risk score system based on a six-microRNA signature predicts the overall survival of patients with ovarian cancer
por: Zhou, Min, et al.
Publicado: (2022)

A 13-Gene Signature Based on Estrogen Response Pathway for Predicting Survival and Immune Responses of Patients With UCEC
por: Li, Yimin, et al.
Publicado: (2022)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance
por: Ferriss, J. Stuart, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_da1la17hhqbl8fo7ark7pjb14s